Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo (1)H-Magnetic Resonance Spectroscopy and Machine Learning

SIMPLE SUMMARY: Approximately 75–80% of according to the classification of world health organization (WHO) grade II and III gliomas are characterized by a mutation of the isocitrate dehydrogenase (IDH) enzymes, which are very important in glioma cell metabolism. Patients with IDH mutated glioma have...

Descripción completa

Detalles Bibliográficos
Autores principales: Bumes, Elisabeth, Wirtz, Fro-Philip, Fellner, Claudia, Grosse, Jirka, Hellwig, Dirk, Oefner, Peter J., Häckl, Martina, Linker, Ralf, Proescholdt, Martin, Schmidt, Nils Ole, Riemenschneider, Markus J., Samol, Claudia, Rosengarth, Katharina, Wendl, Christina, Hau, Peter, Gronwald, Wolfram, Hutterer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698334/
https://www.ncbi.nlm.nih.gov/pubmed/33212941
http://dx.doi.org/10.3390/cancers12113406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698334/
https://www.ncbi.nlm.nih.gov/pubmed/33212941
http://dx.doi.org/10.3390/cancers12113406

Ejemplares similares